Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities
Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity.
The explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor.
These and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.
연구 개요
상세 설명
The investigators hypothesize that SSDH factors drive cancer development differentially by race, and including SSDH factors in prediction models can improve risk prediction to guide decision-making regarding screening, diagnosis, and treatment across race and ethnic groups.
PRIMARY OBJECTIVE:
To identify not yet discovered SSDH and lifestyle factors that associate with identification of unfavorable vs. favorable prostate cancer histology between Black, Hispanic, and Asian men.
OUTLINE:
UCSF participants who agreed to participate in the Urology 90991 Biobank Consent (UCSF internal review board (IRB) #11-05226), and urology surgeons at community hospitals may refer participants for radical prostatectomy to University of California, San Francisco. Potential participants will be approached by the UCSF study team for an offer to participate and Non-UCSF participants will be asked to sign a medical release form prior to the research team collecting data from your medical record about your prostate cancer and treatment.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Kiana Washington
- 전화번호: 415.514.8026
- 이메일: Kiana.Washington@ucsf.edu
연구 연락처 백업
- 이름: Karina Acevedo
- 전화번호: 415.353.7615
- 이메일: Karina.Acevedo@ucsf.edu
연구 장소
-
-
California
-
San Francisco, California, 미국, 94143
- 모병
- University of California, San Francisco
-
연락하다:
- Kiana Washington
- 전화번호: 415.514.8026
- 이메일: Kiana.Washington@ucsf.edu
-
연락하다:
- Karina Acevedo
- 전화번호: 415.353.7615
- 이메일: Karina.Acevedo@ucsf.edu
-
수석 연구원:
- Mathew Cooperberg, MD, MPH
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Participants who have elected radical prostatectomy as prostate cancer treatment.
- Participants who have agreed to participate in the Urology Biobank.
Exclusion Criteria:
- Participant does not plan nor schedule a radical prostatectomy (RP) procedure.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Men with prostate cancer
Participants who have planned or completed a non-investigational radical prostatectomy will be asked to complete a series of questionnaires online covering a subset of community-informed SSDH measures and individual exposures.
Responses will be recorded in a secured database. .
It will take about up to 2 hours to complete the surveys.
There will be questions about your demographics (education level, income, employment, etc.); health care access and quality; lifestyle and behaviors.
Data from your medical record about your prostate cancer and treatment will also be collected.
|
Participants will receive surveys to complete online via a secure system.
다른 이름들:
Data will be collected from participants medical charts which includes disease history, pathological findings, and other disease characteristics.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Identification of not yet identified factors contributing to prostate cancer
기간: Up to 2 years
|
Genomic and SSDH factors will be evaluated to locate not yet identified factors that are associated with greater immune activation and prediction of unfavorable vs. favorable prostate cancer biology by race and ethnicity groups.
|
Up to 2 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Matthew Cooperberg, MD, University of California, San Francisco
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 255517
- U54CA302452 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .